CYP1A1 and renal cell carcinoma: In this study, by the use of the CYP1 inhibitor alpha-naphthoflavone at a low concentration (10 nM), which distinguishes between CYP1A1 and CYP1B1, we showed measurable CYP1B1 activity in RCC.